teams have been handed over to the CBI for a comprehensive enquiry and the enquiry is in progress. Department of Industrial Development had not appointed any other Committee in this regard.

Power requirement of Gujarat

1512. SHRI CHIMANBHAI MEHTA:

SHRI RAMSINGHBHAI PATALIYABHAI RATHVAKOLI:

Will the Minister of ENERGY be pleased to refer to the answer to Unstarred Question 96 given in the Rajya Sabha on the 13th April, 1987 and state:

(a) what is the estimated requirement of electricity of Gujarat at the end of Seventh Five Year Plan and what would be shortfall, if any;

(b) what is the per capita electricity generation and consumption in Maharashtra, Punjab, Tamil Nadu, West Bengal, Delhi and Gujarat;

(c) how does Central Government propose to meet the shortfall in supply of electricity in Gujarat; and

(d) whether the Department would expedite clearance of six major thermal power projects of Gujarat pending clearance since as long as 1981?

THE MINISTER OF STATE IN THE DEPARTMENT OF POWER IN THE MINISTRY OF ENERGY (SHRIMATI SUSHILA ROHATGI): (a) The energy requirement of Gujarat by the end of the Seventh Five Year Plan as estimated by the Twelfth Power Survey would be around 22640 Mkwh and according to present indications, a shortfall of about 14 per cent is possible.

(b) The per capita electricity generation including that of Central Sector is indicated below for 1985-86:—

(Kwh)

State	Per capita electricity generation including Central Sector generation.
Maharashtra .	423·24
Punjab . . .	892·96
Tamil Nadu . .	289·11
West Bengal . .	181·20
Delhi . . .	625·38
Gujarat . . .	365·98

The per-capita electricity consumption in each State during 1985-86 was as follows:-

State	(Per capita electricity consumption Kwh)
Maharashtra .	312·77
Punjab . . .	421·94
Tamil Nadu . .	217·44
West Bengal . .	134·38
Delhi . . .	544·18
Gujarat . .	294·48

(c) In order to reduce the shortfall in supply of electricity in Gujarat, a number of measures are being taken. These *inter-alia* include addition of 1085 MW new generation capacity plan during Seventh Plan in the State of Gujarat, undertaking the renovation and modernisation of the Gandhi Nagar, Ukai and Dhurvaran Thermal Power Stations to maximise generation, reduction of T&D losses, eneregy conservation and transfer of surplus power from neighbouring States|Regions as and when feasible.

(d) Approval of projects is contingent on a number of factors including tying

up of necessary inputs such as fuel availability, environmental clearance, clearance from civil aviation, water availability etc. It is not practical to indicate a specific timeframe for the approval of the schemes.

Exorbitant prices of drugs

1513. SHRI BHUBANESWAR KALITA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the consumer is paying twelve times more than the correct prices of medicines;

(b) whether it is also a fact that the drug companies are still charging exorbitant prices because of the stay orders granted by various High Courts;

(c) the names of the drug companies which obtained stay orders against the price fixation orders of his Ministry;

(d) the names of drugs and formulations alongwith prices being charged by drug companies and prices fixed by his Ministry; and

(e) since when each of these companies got stay orders?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAICHANDRA SINGH): (a) and (b) Some companies are charging their own prices due to stay orders granted by various High Courts.

(c) to (e) Information to the extent available is given in the attached Statement (*See* below). Rest of the details will be collected and laid on the Table of the Rajya Sabha.

Statement

Sl. No.	Name of the Company	Name of the Bulk Drug Formulations
1	2	3
I.	*Delhi High Court :*	
1.	M/s. Glindia (formerly known as M/s. Glaxo Labs. I. Ltd.)	Betamethasone and its formulations.
II.	*Supreme Court of India :*	
1.	M/s. Geoffery Manners	Benzathine Pencilline and its formulations
2.	M/s. Pfizer Ltd.	Oxytertacyline, PAS and its salts and formulations based thereon.
3.	M/s. Hoechst India Ltd.	Baralgan, Pyrolidine Methyl Tetracycline, Pheniframine, Glybenclamide Frusemide, and formulations.
4.	M/s. Parke Davis	Retention price of Chloramphenicol.
5.	M/s. Ethnor Ltd.	Tetramesol and its formulations.
6.	M/s. Anil Starch	Dextrose Anhydrons.
7.	M/s. Merck Sharp & Dohne	Dexamethasone & its formulations.
8.	M/s. Tamil Nadu Dhadha	Calcium Lactate & its formulations.
9.	M/s. Griffon Labs.	Procaine Penciillin V and formulations.